Brind.

Immutep and Merck are combining their therapies, with presentations made at WCLC in Barcelona and engagements held in Paris and Chicago.

1 report, 1 independent Updated Jul 29

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Merck KGaA Immutep

Keep exploring

The entities involved

Merck KGaA
German multinational science and technology company
- MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Mon 12:02
- Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Mon 02:05
Immutep
Biotechnology company
- A lawsuit was filed against the company Immutep in New York City.Sun 21:15

Coverage

Newest first; wire copies grouped

Jul 29GlobeNewswireImmutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP)